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Abstract
Background: The objective of our study was to conduct a cost-effectiveness (CE) study of combined everolimus
(EVE) and exemestane (EXE) versus the common clinical practice in Greece for the treatment of postmenopausal
women with HR+/HER2- advanced breast cancer (BC) progressing on nonsteroidal aromatase inhibitors (NSAI).
The combinations of bevacizumab (BEV) plus paclitaxel (PACL) and BEV plus capecitabine (CAPE) were selected as
comparators.
Method: A Markov model, consisting of three health states, was used to describe disease progression and evaluate
the CE of the comparators from a third-party payer perspective over a lifetime horizon. Efficacy and safety data as
well as utility values considered in the model were extracted from the relevant randomized Phase III clinical trials
and other published studies. Direct medical costs referring to the year 2014 were incorporated in the model.
A probabilistic sensitivity analysis was conducted to account for uncertainty and variation in the parameters of the
model. Primary outcomes were patient survival (life-years), quality-adjusted life years (QALYs), total direct costs and
incremental cost-effectiveness ratios (ICER).
Results: The discounted quality-adjusted survival of patients treated with EVE plus EXE was greater by 0.035 and
0.004 QALYs, compared to BEV plus PACL and BEV plus CAPE, respectively. EVE plus EXE was the least costly
treatment in terms of drug acquisition, administration, and concomitant medications. The total lifetime cost per
patient was estimated at €55,022, €67,980, and €62,822 for EVE plus EXE, BEV plus PACL, and BEV plus CAPE,
respectively. The probabilistic analysis confirmed the deterministic results.
Conclusion: Our results suggest that EVE plus EXE may be a dominant alternative relative to BEV plus PACL and
BEV plus CAPE for the treatment of HR+/HER2- advanced BC patients failing initial therapy with NSAIs.
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Background
Breast cancer (BC) is the most prevalent neoplasm, ac-
counting for 5.2 million cases worldwide [1]. While be-
ing the fifth leading cause of cancer-related deaths, it is
still the most frequent cause of cancer death for women
in both developing and developed regions [2]. It is esti-
mated that about 5 % to 10 % of BCs are metastatic at
diagnosis [3]. Moreover, despite the continuing advances
in therapy, approximately 20 % to 30 % of early BC cases
will eventually become metastatic [4, 5]. In this advanced
stage the cancer can no longer be cured but it can be
controlled for several years.
The disease is associated with a substantial economic
burden due to increased resource utilization. From diagno-
sis to death, the total cost for the management of patients
with metastatic BC (mBC) has been reported to range
from $41,590 to $82,973 (adjusted to 2005 US dollars)
[6–9]. Outpatient services have been found to account
for 29 % of total cost (driven by diagnostic imaging and
radiation therapy), followed by medication other than
chemotherapy (26 %), chemotherapy (25 %), and inpatient
care (20 %) [10]. Interestingly, Medicare data have revealed
that the direct cost is lower in older mBC patients
compared to younger patients, implying that the cost
of illness is inversely proportional to age [9]. Furthermore,
productivity loss and other indirect costs are substantially
higher in mBC patients than in early BC patients or the
general population, underscoring the economic burden
of mBC [11].
The treatment of mBC usually involves hormone therapy
and/or chemotherapy, with or without monoclonal anti-
bodies (i.e. bevacizumab [BEV], trastuzumab [TRZ]). The
cytological and histological documentation of the disease
prior to treatment is essential in order to select the most
effective therapy. In this context, the status and level of
hormone receptors (HR) – estrogen receptors (ER) and
progesterone receptors (PR) – as well as the positivity of
human epidermal growth factor receptor 2 (HER2/neu) at
the time of recurrence should be considered [12].
In cases of postmenopausal women with HR+ advanced
BC, aromatase inhibitors (steroidal or nonsteroidal) are in-
dicated as the standard initial treatment. Nonetheless, the
majority of patients either do not respond to the initial
treatment or develop resistance [13]. Alternative treatment
options, such as ER antagonists (e.g. tamoxifen [ΤΑΜ])
and ER down-regulators (e.g. fulvestrant [FULV]), are con-
sidered of limited efficacy within the frame of endocrine
resistance that occurs after first-line treatment with aro-
matase inhibitors [13, 14]. In July 2012, the European
Commission approved the addition of everolimus (EVE)
to the aromatase inhibitor exemestane (EXE) for the
treatment of post-menopausal women with HR+/HER2-
advanced BC progressing on nonsteroidal aromatase
inhibitors (NSAI: i.e. anastrozole, letrozole). EVE is a
new treatment option that inhibits the hyper-activation
of the mammalian target of rapamycin, a protein that is
associated with BC progression and the development of
endocrine resistance [15]. The clinical benefit of the
EVE plus EXE combination, regardless of ethnicity, was
established through the Phase III BOLERO-2 trial (Breast
cancer trials of OraL EveROlimus-2) [16, 17].
BC patients whose tumors have progressed on hormone
therapy are candidates for chemotherapy [12]. Single
agents, such as paclitaxel (PACL) and capecitabine
(CAPE), have shown efficacy in mBC [18–23]. None-
theless, the addition of BEV – a monoclonal antibody
directed against all isoforms of vascular endothelial growth
factor-A – in PACL or CAPE is common practice and
has been evaluated in clinical trials [24, 25].
Although the addition of EVE to hormone therapy and
BEV to chemotherapy seems to be more efficacious than
the corresponding monotherapies, these combinations
may impose additional costs on third-party payers. How-
ever, the recent climate of the major financial crisis, es-
pecially in Greece, has resulted in strong budgetary
constraints. This fact makes imperative the use of treat-
ments not only clinically effective but also economically
efficient, to maximize the value, in other words the
benefit, of the money spent on health care. This need
has led to the use of economic assessment models to
evaluate the technologies employed in health care systems.
Hence, the objective of the present analysis was to
evaluate the cost-effectiveness of EVE combined with EXE
versus the common clinical practice in Greece for the
treatment of postmenopausal women with HR+/HER2-
advanced BC progressing on NSAI.
Methods
A Markov model was adapted locally to reflect the nat-
ural progression of postmenopausal women with ER
+/HER2-. The model evaluated the cost-effectiveness of
EVE plus EXE versus BEV plus PACL and BEV plus
CAPE over a lifetime horizon. It should be noted that,
although other hormonal therapies or chemotherapies as
monotherapies could be considered as comparators in
the present analysis, they were not selected since they
do not constitute the common clinical practice in Greece,
probably because of their limited efficacy. The analysis
was performed from a payer’s perspective (EOPYY). Costs
and outcomes that occurred beyond one year were dis-
counted at a 3.5 % annual rate, which is the standard prac-
tice in Greece as well as other jurisdictions. No approval
by an appropriate ethical committee was required as no
humans were involved in this study.
Model structure
The Markov model consists of three mutually exclusive
health states: pre-progression, post-progression, and death
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as an absorbing state (Fig. 1). Patients entered the model
at the pre-progression health state and were treated with
one of the model comparators until disease progression
or death. When patients moved to the post-progression
health state they either remained or transitioned to death.
The cycle length of the model was one month.
Target population
The hypothetical cohort of patients entering the Markov
model was assumed to have similar baseline characteristics
to the population included in the Phase III BOLERO-2
randomized clinical trial [16].
Efficacy
The efficacy of treatment in the pre-progression state of
the model was quantified in terms of progression-free
survival (PFS) and overall survival (OS). In particular, in
the base case scenario, the efficacy of EVE plus EXE was
derived from the BOLERO-2 trial data using local radio-
logical assessment, whereas data obtained from central
radiological assessment were used in a sensitivity analysis
[16, 17]. Due to the “lifetime” character of the analysis, OS
and PFS were extrapolated beyond the follow-up period of
the BOLERO-2 trial through the application of parametric
survival curves. The parametric survival curves were esti-
mated using four distributions: exponential-endpoint,
Weibull, exponential-curve, and log-logistic. Based on the
statistical properties of the curve-fitting analysis, the
Weibull distribution was selected as the best-fit curve for
OS and PFS in the base-case analysis. The other parametric
distributions were used in the sensitivity analyses.
To estimate the PFS and OS for the comparators, rele-
vant hazard ratios (HRs) were applied to the OS and
PFS functions of EVE plus EXE. To be more precise, in
the absence of head-to-head clinical trials between EVE
plus EXE and the selected comparators (BEV plus PACL
and BEV plus CAPE), indirect methods and assumptions,
similar to those considered in the model submitted to the
National Institute for Clinical Excellence (NICE) [15],
were used to obtain estimates for HRs of the comparators
against EVE plus EXE. The assumptions and indirect com-
parisons employed to calculate the corresponding HRs for
OS and PFS are depicted in Figs. 2 and 3.
Finally, it was assumed that the post-progression treat-
ment sequences did not affect patients’ survival or qual-
ity of life (i.e. utilities). This assumption is considered
reasonable, since the effect of post-progression treat-
ment is indirectly modeled through the OS related to
the pre-progression treatment. To this end, identical
post-progression treatment sequences were considered
for the comparators and were only allowed to affect
the related costs that arose.
Comparator dosing and administration
The treatment doses for each comparator matched those
used in Phase III clinical trials, so that dosing could be
correlated with clinical efficacy (Additional file 1: Appendix
I). Moreover, patients were assumed to continue treatment
until progression or death. Nonetheless, the relative dose
intensity was also incorporated in the model, allowing for
the fact that some patients may not take the planned dose
for the whole treatment period until progression or death.
The relative dose intensities of EVE and EXE (when these
are coadministered) were derived from the BOLERO-2 trial
(86 % and 100 %, respectively). In view of the lack of
data, the relative dose intensity for the other comparators
was assumed to be equal to that of EVE in the BOLERO-2
trial (86 %)[17].
Safety
In accordance with usual practice, Grade III/IV adverse
events were considered in the model. Among the adverse
events that may be experienced by mBC patients treated
with one of our comparators, only those requiring substan-
tial use of health care resources were considered in
the analysis. Based on local expert opinion, the following
adverse events were considered: nausea, vomiting, pneu-
monitis, allergy, anemia, neutropenia, arthralgia and myal-
gia. The frequency of adverse events was extracted from
relevant clinical trials [16, 24, 25].
Utilities
Utilities in the Markov model were applied to the health
state and were not treatment-related. The pre-progressed
and the post-progressed utility values were derived from
the study of Lloyd et al. [26], as used in several technology
appraisals for mBC submitted to NICE (i.e. FULV, eribulin,
lapatinib and trastuzumab) [15]. Calculations were based
on a sample of the general public in the UK (using the
Standard Gamble technique) and since the people valuing
the health states were younger than the patients in the
BOLERO-2 trial (40.16 as opposed to 62.1), age-adjusted
estimations of utilities were eventually incorporated in the
Fig. 1 Markov model structure
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model (0.7733 for the pre-progression state and 0.4964 for
the post-progression state).
Costing methods
Since the analysis was conducted from the third-party
payer perspective, only direct medical costs reimbursed by
EOPYY were considered in the model (i.e. hospitalization,
physician visits, pre-treatment medications, complementary
or prophylactic treatments, imaging tests, lab tests, and
costs for the management of adverse events). The resource
utilization associated with each health state was based
on local expert opinion. The volumes of resource units
were combined with the corresponding local unit costs
to aggregate a total cost per health state. All costs applied
in the analysis refer to the year 2013.
Pre-progression state costs
Costs in the pre-progression health state comprised ac-
quisition and administration costs for the comparators
and pretreatment medications, as well as costs related to
the disease and adverse events management (i.e. imaging
and lab tests, complementary treatments). Information
about the pretreatment medication, as well as the re-
source utilization related to disease and adverse events
management, were obtained from a local expert to re-
flect the common clinical practice in Greece. In brief,
patients following chemotherapy regimens were con-
sidered to be receiving pretreatment medication and
prophylactic treatment for neutropenia and anemia, as
opposed to patients treated with EVE plus EXE. Moreover,
disease management in the pre-progression state was con-
sidered to include laboratory and imaging tests. Details of
Fig. 2 Assumptions and indirect comparisons to obtain estimations for the overall survival of comparators
Fig. 3 Assumptions and indirect comparisons to obtain estimations for the progression free survival of comparators
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the resource utilization are presented in Additional file 1:
Appendix I.
Drug acquisition and administration costs The drug
acquisition costs were calculated by combining the drug
dosing schedules with the corresponding reimbursed
drug prices. In Greece, the reimbursed drug prices de-
pend on the way each drug is provided in the health care
system (hospital, EOPYY pharmacies, retail pharmacies)
as well as the way these medicines are administered (i.e.
intravenously, orally). In this context, the reimbursed
price was calculated as the hospital price plus a mark-up
of 5 % for BEV and PACL, as the hospital price minus a
rebate of 5 % for EVE, CAPE and other high cost drugs
delivered in the outpatient setting, while for drugs dis-
pensed in community pharmacies (such as EXE), the
reimbursed prices were calculated based on the social
security reimbursement prices and retail prices. Hospital
and retail prices were obtained from the Price Bulletin pub-
lished in August 2013 and social security reimbursement
prices were extracted from the Positive List published
in October 2013.
The costs for disease management of patients in the
pre-progression state as well as the management of ad-
verse events were calculated by multiplying the number
of resource units (obtained from a local expert) with the
corresponding costs per unit (i.e. reimbursed costs, as-
suming that all patients were treated in the public sector).
The costs related to adverse event management were one-
off costs. All unit costs are presented in Additional file 2:
Appendix II, while the total pre-progressed cost per cycle
is presented in Table 1.
Post-progression state costs
In the post-progression state, for all comparators, it
was assumed that patients were assigned to one of two
mutually exclusive treatment strategies, based on a local
expert’s opinion. To be more precise, 50 % of patients ex-
periencing disease progression, regardless of the treatment
received in the pre-progression state, were considered
to be treated with a 3rd line hormonal therapy (i.e. FULV),
a 4th line chemotherapy (i.e. docetaxel [DOC]) and then
with supportive palliative care (lonarid/fentanyl patches),
whereas the remaining 50 % of patients received chemo-
therapy as 3rd (CAPE plus Vinorelbine) and 4th line
treatment (DOC) and then supportive palliative care.
Additional file 3: Appendix III shows in detail the re-
sources employed during treatment, dosing schedules,
average hospitalization and monitoring requirements .
In order to calculate the average cost per month in the
post-progression state, the monthly cost was calculated
for each treatment line (3rd and 4th) in the two alternative
strategies (drug costs, monitoring costs and hospitalization
costs). Subsequently, for each strategy, the monthly cost
per treatment line was weighted based on its duration (i.e.
12 months, 6 months) to obtain a total treatment strategy
cost. Finally, based on the patients’ allocation to these
strategies, as indicated by the medical expert (50 %-50 %),
the average cost per month in the post-progression state
was calculated.
The drug acquisition costs as well as the monitoring
costs were calculated as described in the pre-progression
state. The total post-progressed cost per cycle used in
the analysis is presented in Table 1.
Data analysis
The cost-effectiveness of EVE plus EXE over the compara-
tors BEV plus PACL and BEV plus CAPE was evaluated by
calculating the incremental cost-effectiveness ratio (ICER).
For a treatment to be considered cost-effective, a willing-
ness-to-pay (WTP) threshold of €36,000 per quality-
adjusted life year (QALY) gained was used in the current
analysis. This is based on the WHO guidelines, which
state that a treatment should be considered cost-effective
if the ICER is between 1 and 3 times the GDP per capita
of that country and a treatment is considered highly cost
effective at less than 1 times the GDP per capita [27]. The
GDP per capita in Greece was estimated at €17,000, taken
from the IMF estimation of GDP per capita using current
prices [28].
Sensitivity analyses were undertaken to test the robust-
ness of the results, by varying either individual parameters
between low and high values within plausible ranges or
the structural assumptions adopted in the model. How-
ever, the majority of parameters used in the current model
are subject to variation. Therefore, in order to deal with
uncertainty, a probabilistic sensitivity analysis (PSA) was
performed using a Monte Carlo simulation. In this ana-
lysis, probability distribution was assigned around each
parameter (i.e. costs, utilities, etc.) and cost-effectiveness









Drug acquisition cost 2,447.75 € 3,806.42 € 3,510.97 €
Administration cost 0 € 260.89 € 115.95 €
Pre-treatment costs 0 € 82.58 € 36.69 €
Lab tests 42.82 € 52.41 € 48.25 €
Monitoring cost 52.34 € 52.34 € 52.34 €
Prophylactic treatment cost - 274.72 € 416.77 €
Total post-progression cost/
cycle
1,057.41 € 1,057.41 € 1,057.41 €
End-of-life cost 823.60 € 823.60 € 823.60 €
EVE: everolimus; EXE: exemestane; BEV: bevacizumab; PACL: paclitaxel;
CAPE: capecitabine
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results associated with simultaneously selecting random
values from those distributions were generated. In particu-
lar, utility values are restricted to the interval zero to
one, and hence they were varied according to a beta
distribution. The gamma distribution and the lognormal
distribution were applied for the cost and effectiveness
variables, respectively.
One thousand estimates of costs, QALYs, and incremen-
tal cost per QALYgained were then obtained by performing
the bootstrapping technique. A cost-effectiveness accept-
ability curve (CEAC) was plotted, showing the proportion
of simulations that are considered cost-effective at different
levels of willingness to pay per QALY gained.
Results
Deterministic results
The Markov model predicted that the discounted quality-
adjusted survival of patients treated with EVE plus EXE
would be greater compared to those treated with BEV plus
PACL and BEV plus CAPE, by 0.035 and 0.004 QALYs, re-
spectively. Moreover, the total lifetime cost per patient for
EVE plus EXE, BEV plus PACL, and BEV plus CAPE was
estimated to be €55,022, €67,980, and €62,822, respectively.
Hence, the use of EVE plus EXE may result in a cost saving
of €12,958 over BEV plus PACL and €7,800 over BEV plus
CAPE. The observed difference in the total lifetime cost
between EVE plus EXE and BEV plus PACL was mainly
attributable to the drug acquisition and administration
cost (EVE plus EXE: €25,727 vs. BEV plus PACL: €32,960),
since BEV and PACL, apart from being a more expensive
treatment combination, was associated with higher admin-
istration costs. Furthermore, BEV plus PACL was associ-
ated with a significantly higher pre-progression cost (EVE
plus EXE: €1,000 vs. BEV plus PACL: €3,744), which may
be attributed to the pre-treatment medications as well as
the prophylactic treatments required. The higher pre-
progression cost of the BEV plus CAPE arm (€3,946)
accounted for the difference in the total lifetime cost be-
tween EVE plus EXE and BEV plus CAPE, while the BEV
plus CAPE alternative generated an incremental cost of
€4,813 in the post-progression state (EVE plus EXE:
€27,495 vs. BEV plus CAPE: €32,308) (Table 2).
Based on the above, EVE plus EXE seems to be a dom-
inant alternative over BEV plus PACL and BEV plus
CAPE in a lifetime horizon, as the first combination is
associated with a greater health benefit and a lower total
lifetime cost (Table 2).
Sensitivity analysis
In addition, sensitivity analyses of the model were per-
formed, regarding the method used to extrapolate OS
and PFS data. The choice of parametric distribution was
found to have an effect on the main findings of our
study, but only in terms of the comparison between EVE
plus EXE and BEV plus CAPE. To be more precise, EVE
plus EXE was a dominant option over BEV plus PACL,
Table 2 Base case results for EVE plus EXE vs. BEV plus PACL and BEV plus CAPE for the treatment of ER+ mBC patients
Incremental analysis
Outcomes EVE plus EXE BEV plus PACL BEV plus CAPE BEV plus PACL BEV plus CAPE
Treatment and administration costs* 25,727 € 32,960 € 25,832 € −7,233 € −105 €
AE costs (grade 3/4)* 62 € 5 € 1 € 57 € 61 €
Pre-progression background costs* 1,000 € 3,744 € 3,946 € −2,744 € −2,946 €
Post-progression background costs* 27,495 € 30,534 € 32,308 € −3,039 € −4,813€
Terminal care costs* 737.51 € 736.41 € 734,77 € 1.10 € −2.74 €
Total costs* 55,022 € 67,980 € 62,822 € −12,958 € −7,800 €
QALYS*: Pre-progressed 0.648 0.494 0.456 0.154 0.192
QALYS*: Post-progressed 1.076 1.195 1,264 −0.119 −0.188
Total QALYS* 1.724 1.689 1,720 0.035 0.004
Life years†: Pre-progressed 0.899 0.689 0.604 0.210 0.295
Life years†: Post-progressed 2.422 2.679 2.833 −0.257 −0.411
Total undiscounted life years† 3.321 3.368 3.437 −0.047 −0.116
Life years*: Pre-progressed 0.876 0.675 0.594 0.201 0.282
Life years*: Post-progressed 2.167 2.406 2.546 −0.240 −0.379
Total discounted life years* 3.043 3.082 3.140 −0.039 −0.097
Incremental cost per QALY Dominant Dominant
Incremental cost per LY Less effective Dominant
*discounted †undiscounted
EVE: everolimus; EXE: exemestane; BEV: bevacizumab; PACL: paclitaxel; CAPE: capecitabine; QALY: quality-adjusted-life years; mBC: metastatic breast cancer; LY: life year
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regardless of the parametric distribution used to extrapo-
late OS and PFS, but it was deemed less effective with
respect to BEV plus CAPE, when the exponential (end-
point), Gompertz or exponential (curve) distributions
were applied (Table 3).
Finally, the one-way sensitivity analysis revealed that
the results of our study were mainly driven by the PFS
and OS data as well as the drug acquisition costs. In this
context, EVE plus EXE was not a dominant alternative,
but remained cost-effective over BEV plus PACL when
Table 3 Results from the sensitivity analysis
Base case ICER Dominant Low value High Value
Parameter Base case value High value ICER Low value ICER
PFS: EVE plus EXE vs. BEV plus PACL (−50 %; +50 %) 50 % 1,384 € 150 % Dominant
PFS: BEV plus PACL (−50 %; +50 %) 50 % Dominant 150 % Dominant
PFS: EVE plus EXE vs. BEV plus CAPE (−50 %; +50 %) 50 % 26,091 € 150 % Dominant
PFS: BEV plus CAPE (−50 %; +50 %) 50 % Dominant 150 % Dominant
OS: EVE plus EXE vs. BEV plus PACL (−50 %; +50 %) 50 % €11,251 € 150 % Dominant
OS: BEV plus PACL (−50 %; +50 %) 50 % Dominant 150 % Dominant
OS: EVE plus EXE vs. BEV plus CAPE (−50 %; +50 %) 50 % 17,104 € 150 % Dominant
OS: BEV plus CAPE (−50 %; +50 %) 50 % Dominant 150 % 5,876 €
Fixed post-progression survival (6–48 months) 12 6 Dominant 48 Dominant
Utility: pre-progression (0.36; 0.90) 0.773 0.36 Dominant 0.90 Dominant
Utility: post-progression (0.2; 0.97) 0.496 0.22 Dominant 0.97 Dominant
Pre-progression background costs (50 €; 150 €) 95.16 € 50.00 € Dominant 150 € Dominant
Post-progression background costs (500 €; 1500 €) 1,057.41 € 500.00 € Dominant 1,500 € Dominant
Adverse event costs: EVE plus EXE (38 €; 133 €) 62 € 37.89 € Dominant 133 € Dominant
Adverse event costs: BEV plus PACL (4.92 €; 34 €) 5.14 € 4.92 € Dominant 34 € Dominant
Adverse event costs: BEV plus CAPE (0.50 €; 34 €) 1 € 0.50 € Dominant 34 € Dominant
Adverse event disutilities: EVE plus EXE (0.011; 0.04) −0.029 −0.011 Dominant −0.04 Dominant
Adverse event disutilities: BEV plus PACL (0.005; 0.069) 0.027 −0.005 Dominant −0.069 Dominant
Adverse event disutilities: BEV plus CAPE (0.005; 0.069) −0.0031 −0.002 Dominant −0.069 Dominant
Adverse events: unknown disutility assumption (−0.01; −0.10) −0.05 −0.013 Dominant −0.100 Dominant
BOLERO II Central PFS included Without With Dominant
Fixed post-progression survival applied Without With Dominant
Dose intensity included Without With Dominant
Drug cost: EVE plus EXE vs. BEV plus PACL (2000 €; 5000 €) 2,447.75 € 2000 € Dominant 5,000 € 324,159 €
Drug cost: BEV plus PACL (2000 €; 5000 €) 3,806.42 € 2000 € 151,243 € 5,000 € Dominant
Drug cost: EVE plus EXE vs. BEV plus CAPE (2000 €; 5000 €) 2,447.75 2000 € Dominant 5,000 € 4,082,144 €
Drug cost: BEV plus CAPE (2000 €; 5000 €) 3,510.97€ 2000 € 3,539,497 € 5,000 € Dominant
Extrapolation method (EVE plus EXE versus comparator)
Exponential, endpoint (PACL) Dominant
Exponential, endpoint (CAPE) Less effective
Gompertz (PACL) Dominant
Gompertz (CAPE) Less effective
Exponential, curve (PACL) Dominant
Exponential, curve (CAPE) Less effective
Log-logistic(PACL) Dominant
Log-logistic (CAPE) Dominant
EVE: everolimus; EXE: exemestane; BEV: bevacizumab; PACL: paclitaxel; CAPE: capecitabine; ICER: incremental cost effectiveness ratio; PFS: progression free survival; OS:
overall survival
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the PFS of EVE plus EXE was reduced by 50 % (ICER:
€1,384). Likewise, when the OS of EVE plus EXE was de-
creased by 50 % the resulting ICER reached €11,251 – well
below the predetermined WTP threshold of €36,000 per
QALY gained. Similarly, in the comparison of EVE plus
EXE over BEV plus CAPE, the former was a cost-effective
alternative when its PFS and OS were reduced by 50 %
(ICER: €26,091 and ICER: €17,104, respectively) and when
the OS of BEV plus CAPE was increased by 50 % (ICER:
€5,876). All these results are presented in Table 3.
Probabilistic sensitivity analysis
The PSA confirmed the deterministic results (Fig. 4).
The CEAC showed that EVE plus EXE was cost-effective
over BEV plus PACL in 95.5 % of cases and over BEV
plus CAPE in 87.2 %, at a WTP of €36,000.
Discussion
In the present study, a Markov model was adapted to
assess the cost-effectiveness of EVE plus EXE against
BEV plus CAPE and BEV plus PACL for the treatment
of ER+/HER2- advanced BC in the Greek health care
setting. The parameters considered in the Markov model
were obtained from the literature and a local expert. Ac-
cording to the base case results, EVE plus EXE dominates
both active comparators, as it is associated with lower
costs and higher clinical efficacy in both cases.
At this point, it should be highlighted that this is the
first study to evaluate the cost-effectiveness of EVE plus
EXE over chemotherapy plus BEV in postmenopausal
women with ER + BC. The manufacturer of EVE had sub-
mitted an economic evaluation of EVE plus EXE for treat-
ing HR+/HER2- advanced BC after endocrine therapy for
review by the NICE. The comparators considered in this
previous analysis by the manufacturer were EXE alone,
TAM, FULV, DOC, doxorubicin (DOX), and CAPE. Ac-
cording to the base case results of the manufacturer,
EVE plus EXE compared to EXE alone generated incre-
mental costs of £27,086, as well as 0.84 incremental
QALYs (ICER: £32,417/QALY). Compared to TAM, EVE
plus EXE had an ICER of £29,109 per QALY gained. Re-
garding the comparison with FULV, the EVE plus EXE
arm resulted in additional costs of £20,937 and 0.77 incre-
mental QALYs (£27,147/QALY). For the comparison with
DOC, EVE plus EXE provided an ICER of £11,000 per
QALY gained (£13,364 incremental costs and 1.21 incre-
mental QALYs). EVE plus EXE versus DOX had an ICER
of £20,253 per QALY gained, while with respect to CAPE,
EVE plus EXE was more costly by £29,597 and more
effective by 1.21 QALYs (ICER: £24,362/QALY). None-
theless, based on the Evidence Review Group analysis
that used a non-parallel exponential model and local
PFS measurements, the EVE plus EXE arm versus EXE
was not cost-effective, as it provided an ICER of £68,000
per QALY gained.
The analysis pursued was characterized by specific
drawbacks and limitations. First of all, limitations in the
model arise from the nature of the underlying data,
which in several cases were not available with the required
level of detail. In order to overcome this impediment,
conservative assumptions and indirect comparisons
were made (i.e. similar clinical efficacy for chemotherapy
agents) that could raise issues of structural uncertainty
Nonetheless, indirect comparison is considered as a valid
method as long as large direct comparative trials are lack-
ing. In particular, the approach of indirect comparison is
possible in cases where trials are consistent in terms of the
outcomes used as endpoints, the way these outcomes
are reported, the baseline population, the dosages of
medication, and the follow-up time. Another limitation of
Fig. 4 Cost-Effectiveness Acceptability Curves
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the study was the assumption that the post-progressed
treatment sequences did not affect survival or utility but
only the costs arising; nonetheless, this was a structural
and essential assumption in the core model due to the lack
of data on the efficacy of these treatment sequences. This
assumption was considered valid in the core model, as the
benefit should already have been accounted for in the OS
data from the clinical trials. In addition, in the absence of
mBC patient registries in Greece, the methodology to
collect resource use data may be susceptible to bias
(specialized key opinion leader [KOL]) but it still repre-
sents one of the recommended methods for collecting re-
source utilization data. Finally, it should be noted that the
results have to be considered strictly in the Greek setting
and on the basis of the present time resource and drug
prices. If any of the underlying parameters change, so may
the results and the conclusions of the analysis, resulting in
limited external validity of the model and the outcomes.
Nonetheless, a series of sensitivity analyses indicated that
our model and outcomes are valid, since the main results
remained unchanged.
Conclusions
Using conservative assumptions, the present economic
evaluation suggests that EVE plus EXE provides greater
adjusted survival and is less costly compared to BEV
plus PACL and BEV plus CAPE. Therefore, EVE plus
EXE should be considered as a cost-saving intervention
in Greek health care for the management of postmeno-
pausal women with HR+/HER2- advanced BC progressing
on NSAI.
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